These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 4760536)

  • 1. Mechanism of blocking by hyperimmune serum of lymphocyte-mediated cytolysis of allogeneic tumor cells.
    Todd RF; Stulting RD; Berke G
    Cancer Res; 1973 Dec; 33(12):3203-8. PubMed ID: 4760536
    [No Abstract]   [Full Text] [Related]  

  • 2. Activation of specific cellular immunity toward murine leukemia in mice rejecting syngeneic somatic hybrid cells.
    Liang W; Cohen EP
    J Immunol; 1977 Sep; 119(3):1054-60. PubMed ID: 302270
    [No Abstract]   [Full Text] [Related]  

  • 3. Functional efficiency of antitumor cytotoxic lymphoid cells.
    Wunderlich JR; Martin WJ; Macdonald J
    Isr J Med Sci; 1973 Mar; 9(3):317-23. PubMed ID: 4710039
    [No Abstract]   [Full Text] [Related]  

  • 4. Temperature control of lymphocyte-mediated cytotoxicity in vitro.
    Berke G; Sullivan KA
    Transplant Proc; 1973 Mar; 5(1):421-3. PubMed ID: 4695950
    [No Abstract]   [Full Text] [Related]  

  • 5. Studies on the induction and expression of T cell-mediated immunity. II. Antiserum blocking of cell-mediated cytolysis.
    Bonavida B
    J Immunol; 1974 Apr; 112(4):1308-21. PubMed ID: 4592598
    [No Abstract]   [Full Text] [Related]  

  • 6. Induction of lymphocyte-mediated cytotoxicity against allogeneic tumor cells by concanavalin A in vivo.
    Anaclerio A; Waterfield JD; Möller G
    J Immunol; 1974 Sep; 113(3):870-5. PubMed ID: 4413847
    [No Abstract]   [Full Text] [Related]  

  • 7. Evidence for the suppression of the development of cytotoxic lymphoid cells in tumor immunized mice.
    Martin WJ; Esber E; Wunderlich JR
    Fed Proc; 1973 Feb; 32(2):173-9. PubMed ID: 4688656
    [No Abstract]   [Full Text] [Related]  

  • 8. Production of tumor-specific antibody in the xenogeneic host: use of blocking antibody.
    Weiner RS; Hubbard JD; Mardiney MR
    J Natl Cancer Inst; 1972 Oct; 49(4):1063-70. PubMed ID: 4117316
    [No Abstract]   [Full Text] [Related]  

  • 9. Generation of non-complement-fixing, blocking factors by lysosomal extract treatment of cytotoxic anti-tumor antibodies.
    Dauphinee MJ; Talal N; Witz IP
    J Immunol; 1974 Sep; 113(3):948-53. PubMed ID: 4413555
    [No Abstract]   [Full Text] [Related]  

  • 10. Inhibition of lymphocyte-mediated cytotoxicity (51Cr-release) by antisera preabsorbed with various cells.
    Sendo F; Aoki T; Buafo CK
    J Natl Cancer Inst; 1974 Mar; 52(3):769-75. PubMed ID: 4857026
    [No Abstract]   [Full Text] [Related]  

  • 11. Specificity of antileukemia sera prepared by immunization with leukemia cells admixed with normal antigen-blocking sera.
    Smith PJ; Robinson CM; Reif AE
    Cancer Res; 1974 Jan; 34(1):169-75. PubMed ID: 4129197
    [No Abstract]   [Full Text] [Related]  

  • 12. Suppressed development of cytotoxic lymphoid cells in tumor-immunized mice.
    Martin WJ; Wunderlich JR; Macdonald J
    Isr J Med Sci; 1973 Mar; 9(3):324-31. PubMed ID: 4710040
    [No Abstract]   [Full Text] [Related]  

  • 13. The influence of normal serum components on lymphocyte-mediated cytolysis in vitro.
    Kemp AS; Berke G; Dawson JR; Amos DB
    Transplantation; 1974 May; 17(5):447-52. PubMed ID: 4827317
    [No Abstract]   [Full Text] [Related]  

  • 14. [Cytotoxic and blocking antibodies in the sera and eluates from spleen cells of mice with Rauscher leukemia following a different course].
    Ter-Grigorov VS; Dzagurov SG; Shevelev BI
    Biull Eksp Biol Med; 1975 Feb; 79(2):76-80. PubMed ID: 48386
    [No Abstract]   [Full Text] [Related]  

  • 15. Enzymatic enhancement of cell-mediated cytotoxicity and antibody-dependent cell cytotoxicity.
    Kedar E; Otiz de Landazuri M; Fahey JL
    J Immunol; 1974 Jan; 112(1):26-36. PubMed ID: 4812174
    [No Abstract]   [Full Text] [Related]  

  • 16. Polymorphonuclear leukocytes in antibody-dependent cellular cytotoxicity.
    Gale RP; Zighelboim J
    J Immunol; 1975 Mar; 114(3):1047-51. PubMed ID: 1167565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The activity of regional nodes in the evolution of immune responses to allogeneic and isogeneic tumors.
    Barna B; Deodhar SD
    Cancer Res; 1975 Apr; 35(4):920-6. PubMed ID: 1116149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytotoxic immune cells with specificity for defined soluble antigens. V. Interaction of antibody with the cytotoxic effector cells in immune or non-immune mouse spleen cells.
    Schirrmacher V; Rubin B; Pross H
    J Immunol; 1974 Jun; 112(6):2219-26. PubMed ID: 4856907
    [No Abstract]   [Full Text] [Related]  

  • 19. Immune responses to virus induced experimental leukemia and to human leukemia.
    Herberman RB
    Johns Hopkins Med J Suppl; 1974; 3():3-14. PubMed ID: 4371287
    [No Abstract]   [Full Text] [Related]  

  • 20. Secondary cytotoxic tumor immune response induced in vitro.
    Röllinghoff M
    J Immunol; 1974 May; 112(5):1718-25. PubMed ID: 4544796
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.